Alberto Garaventa

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 123 publications

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Evolution of robotic-assisted resection of pediatric neuroblastic tumors: a retrospective analysis.

Evolution of robotic-assisted resection of pediatric neuroblastic tumors: a retrospective analysis.

Journal: Updates in surgery

Published: May 02, 2026

Missense but mis-spliced: germline TP53 variant c.671A > C (p.E224A) and the path from uncertainty to pathogenicity.

Missense but mis-spliced: germline TP53 variant c.671A > C (p.E224A) and the path from uncertainty to pathogenicity.

Journal: Scientific reports

Published: March 09, 2026

Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.

Retrospective Analysis of Incidence and Etiology of Severe Infections in Children Receiving Therapy for High-Risk Neuroblastoma: A Large Single-Center Experience.

Journal: Pediatric blood & cancer

Published: January 14, 2026

Predicting Clinical Deterioration in Pediatric Hematology-Oncology Patients: PEWS Scales-A Scoping Review.

Predicting Clinical Deterioration in Pediatric Hematology-Oncology Patients: PEWS Scales-A Scoping Review.

Journal: Journal of pediatric hematology/oncology nursing

Published: December 13, 2025

A Computational Approach to Evaluating Empirical Antibiotic Coverage for Gram-Negative Bloodstream Infections in Pediatric Febrile Neutropenia.

A Computational Approach to Evaluating Empirical Antibiotic Coverage for Gram-Negative Bloodstream Infections in Pediatric Febrile Neutropenia.

Journal: Antibiotics (Basel, Switzerland)

Published: December 09, 2025

Novel imaging predictors in pediatric lymphoma: radiomics and artificial intelligence. A systematic review.

Novel imaging predictors in pediatric lymphoma: radiomics and artificial intelligence. A systematic review.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...

Published: November 11, 2025

Correction to: Predictive and prognostic role of volumetric analyses and lymphoma dissemination in pediatric HL: a prospective, multicenter, cohort study.

Correction to: Predictive and prognostic role of volumetric analyses and lymphoma dissemination in pediatric HL: a prospective, multicenter, cohort study.

Journal: European journal of nuclear medicine and molecular imaging

Published: November 11, 2025

Membrane IL-18 identifies a human macrophage subset with distinct proteomic and functional traits.

Membrane IL-18 identifies a human macrophage subset with distinct proteomic and functional traits.

Journal: Oncoimmunology

Published: November 06, 2025

Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.

Immunoprofiling, sex- and age-related determinants of treatment response in paediatric, adolescent and young adult Hodgkin lymphoma.

Journal: British journal of haematology

Published: November 05, 2025

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Journal: Frontiers in oncology

Published: October 30, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers

Published: July 24, 2025

Showing 1-12 of 123

Last Updated: 09/26/2026